Look back at pharma news in week to July 20

By Barbara Obstoj-Cardwell. Editor

There was a sigh of relief last week, when UK Members of Parliament voted for ongoing participation in the European Medicines Agency. On the regulatory front, there was good news for Advaxis when the US Food and Drug Administration lifted the clinical hold on a cancer drug combination axalimogene filolisbac (AXAL) in combination with durvalumab. Also, the FDA’s ‘Biosimilars Action Plan’ is seen as a positive step in the chase for value-based pricing. In terms of clinical trials, Roche’s latest flu drug baloxavir marboxil is showing promise. Biogen was up on positive new data on BAN2401, an Alzheimer’s drug candidate which was largely written off, and Allergan and Molecular Partners achieved positive results with abicipar in wet age-related macular degeneration.

UK biopharma sector wins small victory amid Brexit chaos